Geron Corporation

Geron Corporation reported second-quarter 2026 revenue of US$57.48 million, up from US$49.04 million a year earlier, and a net loss of US$16.68 million, while issuing its first full-year 2026 RYTELO net product revenue guidance of US$220 million to US$240 million. First-half revenue reached US$109.32 million and the first-half net loss narrowed to US$20.32 million. The company also filed a US$6.03 million common stock shelf registration for 4,500,000 shares tied to an employee stock ownership plan. The reiterated guidance sharpens focus on the launch trajectory of Geron's sole commercial therapy, RYTELO, as the company remains dependent on a single drug and faces ongoing cash needs.

Several biotech companies posted sharp gains on Wednesday, led by Attovia Therapeutics' 28% surge on its Nasdaq debut and American Well's 25% jump after narrowing its quarterly loss. Attovia priced its IPO at $17 per share and closed at $21.90, while American Well reported a net loss of $9.6 million, or $0.59 per share, down from $19.5 million, or $1.24 per share, a year earlier, though revenue fell to $52.0 million from $70.9 million. Perrigo swung to a net income of $74.5 million, or $0.53 per share, from a loss of $8.4 million, or $0.06 per share, despite a slight revenue dip to $1.02 billion. UroGen Pharma climbed over 16% after total revenue more than doubled to $72.5 million, driven by its bladder cancer drug ZUSDURI, and its net loss narrowed to $14.4 million from $49.9 million. Geron rose 21% as net product revenue increased to $57.5 million from $49.0 million, fueled by higher RYTELO sales, and it forecast full-year RYTELO revenue of $220 million to $240 million.

Geron Corporation has appointed Chinmaya Rath as its new Chief Business Officer. Rath brings over 25 years of biopharma leadership experience, including a significant tenure at Novartis where he led enterprise-wide strategic initiatives such as the integrations of GSK Oncology and Alcon. Most recently, he served as Head of Pharma Solutions at Cellworks and Chief Business Officer at GlycoMimetics. Geron's President and CEO Harout Semerjian stated that Rath's appointment underscores the company's dedication to maximizing the value of RYTELO globally and building a leading hematology company. Rath highlighted RYTELO's best-in-class profile and strong commercial performance in lower-risk myelodysplastic syndromes as positioning Geron for continued growth.